TACT2.

Study name	Trial to Assess Chelation Therapy 2 (TACT2)
Methods	Phase 3, double‐blind, RCT, 2 x 2 factorial design
Participants	1200 participants with diabetes and prior myocardial infarction
Interventions	Active disodium EDTA (chelation) + active oral multi vitamins/minerals (OMVM) Active disodium EDTA (chelation) + placebo OMVM Placebo disodium EDTA (chelation) + active OMVM Placebo disodium EDTA (chelation) + placebo OMVM
Outcomes	Composite of all‐cause mortality, myocardial infarction, stroke, coronary revascularisation or hospitalisation for unstable angina over 5 years
Starting date	October 2016
Contact information	Gervasio Lamas, MD, TACT2 Study Chair, Mt. Sinai Medical Center, Miami, Florida, United States
Notes	Expected completion in 2021